Ruby-Red Corvette Coupe Raises Funds for TGen, Again
Imagine buying a classic Chevy Corvette for just $50.
This week, that’s the price of one ticket for a 1993 Chevrolet Corvette 40th Anniversary coupe being raffled at the 42nd annual Barrett-Jackson Collector Car Auction in Scottsdale to benefit cancer research at the Translational Genomics Research Institute.
Proceeds go to the Barrett-Jackson Cancer Research Fund at TGen, in Memory of Russ and Brian Jackson. The fund, established in 2010, is a salute to auction Chairman and CEO Craig Jackson’s father, Russ, and brother, Brian, whose lives were cut short by colon cancer.
“The Barrett-Jackson/TGen fund supports colon and prostate cancer research with the hope that new laboratory discoveries will pave the way for better treatments and improved quality of life for cancer patients,” Craig Jackson says. “I am vey honored by the work TGen scientists are pursuing in memory of my dad and brother.”
The ruby-red 1993 Corvette is one of the 40th anniversary models of this legendary sports car. The first Corvette was built in 1953.
If the description of this car seems familiar, it is because the car is the same one that has been auctioned, and then donated back to Barrett-Jackson, raising more than $300,000 in the past two years for TGen’s nonprofit research.
This year, the Corvette will be raffled. Tickets are $50 each, or three for $100. Raffle tickets will be sold Jan. 13 through Jan. 19 during the Barrett-Jackson Collector Car Auction at the TGen booth on the northeast corner of the SPX Showcase Pavilion, or online through Jan. 18 at bjcancerfund.org. The Corvette will be on display at the TGen booth. The raffle winner will be notified Jan. 20.
Although the raffle is being held at the auction, this promotion is being conducted by the TGen Foundation.
“Craig Jackson and his team at Barrett-Jackson have become a tremendous force for TGen, not only in raising funds for cancer research, but in providing enhanced awareness of these diseases and the possibilities available through personalized medicine, treating each patient based on their unique genetic profile,” says Michael Bassoff, president of the nonprofit TGen Foundation.
